| 1 | example | 4,235 |
| 2 | instance | 587 |
| 3 | spp. | 513 |
| 4 | sp. | 241 |
| 5 | periodicals | 220 |
| 6 | illustration | 154 |
| 7 | kliniske | 19 |
| 8 | children-revised | 11 |
| 9 | pathotype | 10 |
| 10 | latreille | 8 |
| 11 | orally-active | 7 |
| 12 | h1a | 6 |
| 13 | tetanus-toxoid | 6 |
| 14 | 1xh5n1-as | 5 |
| 15 | 2xh5n1-as | 5 |
| 16 | children-2 | 5 |
| 17 | ng.hr/ml | 5 |
| 18 | s-h | 5 |
| 19 | alwa | 4 |
| 20 | encapsulant | 4 |
| 21 | nonabuse | 4 |
| 22 | photorejuvenation | 4 |
| 23 | pre-1990 | 4 |
| 24 | revision-augmentation | 4 |
| 25 | spf24nae | 4 |
| 26 | strain/strength | 4 |
| 27 | video-only | 4 |
| 28 | antiprogestogen | 3 |
| 29 | children-iii | 3 |
| 30 | copmi-children | 3 |
| 31 | dose/mass | 3 |
| 32 | ergonomist | 3 |
| 33 | glutelins | 3 |
| 34 | hitters | 3 |
| 35 | hpv-59 | 3 |
| 36 | i.n. | 3 |
| 37 | loss-from-care | 3 |
| 38 | non-registration | 3 |
| 39 | panniculectomy/abdominoplasty | 3 |
| 40 | retweets | 3 |
| 41 | rs588765 | 3 |
| 42 | yhl-i | 3 |
| 43 | -accuracy | 2 |
| 44 | 30min/d | 2 |
| 45 | 5-dsf | 2 |
| 46 | 515-3p | 2 |
| 47 | 517a | 2 |
| 48 | 517c | 2 |
| 49 | 6-dsf | 2 |
| 50 | acri/arb | 2 |
| 51 | age-homogenous | 2 |
| 52 | ambar/fsp | 2 |
| 53 | angora-cont | 2 |
| 54 | antedrugs | 2 |
| 55 | benzene-acetylene | 2 |
| 56 | benzyl-itc | 2 |
| 57 | bio-fuels | 2 |
| 58 | content/quantity | 2 |
| 59 | co₂tisn | 2 |
| 60 | ct-imaging | 2 |
| 61 | cyp2a61b | 2 |
| 62 | data-sets | 2 |
| 63 | day-matched | 2 |
| 64 | deed | 2 |
| 65 | distilisation | 2 |
| 66 | endo-inulinase | 2 |
| 67 | ever-symptoms | 2 |
| 68 | fat/water | 2 |
| 69 | fne48 | 2 |
| 70 | four-days | 2 |
| 71 | granulosum | 2 |
| 72 | h1-blocker | 2 |
| 73 | hazardless | 2 |
| 74 | incana | 2 |
| 75 | interaction=0.01 | 2 |
| 76 | j84.1 | 2 |
| 77 | khuzestanica | 2 |
| 78 | lactation/kg | 2 |
| 79 | lns-10gm | 2 |
| 80 | lns-20gnom | 2 |
| 81 | longituba | 2 |
| 82 | lps-cadmium | 2 |
| 83 | mezlocillin/sulbactam | 2 |
| 84 | mirabilis.recent | 2 |
| 85 | nano-pcpdtbse | 2 |
| 86 | nano-pcpdtbt | 2 |
| 87 | nanolization | 2 |
| 88 | needle-less | 2 |
| 89 | nephroureterctomy | 2 |
| 90 | octa-decabdes | 2 |
| 91 | pain/anxiety | 2 |
| 92 | pandolfi | 2 |
| 93 | parallel-beam | 2 |
| 94 | pemetrexed-carboplatin-enzastaurin | 2 |
| 95 | pennsylvanians | 2 |
| 96 | permp-a | 2 |
| 97 | piperacillin/sulbactam | 2 |
| 98 | pre-coagulation | 2 |
| 99 | proximus | 2 |
| 100 | pten/pi-3k | 2 |
| 101 | puerperant | 2 |
| 102 | re-impregnation | 2 |
| 103 | researchthere | 2 |
| 104 | rs-scn | 2 |
| 105 | rs274622 | 2 |
| 106 | sdhb | 2 |
| 107 | spassky | 2 |
| 108 | spectrophotometrical | 2 |
| 109 | stst-opt | 2 |
| 110 | tegobuvir/gs-9256 | 2 |
| 111 | tegobuvir/gs-9256/rbv | 2 |
| 112 | terbogrel | 2 |
| 113 | thorell | 2 |
| 114 | transport-i | 2 |
| 115 | trend=0.012 | 2 |
| 116 | tricyanofluoroborate | 2 |
| 117 | venlafaxine-mirtazapine | 2 |
| 118 | z907 | 2 |
| 119 | δ6-elongase | 2 |
| 120 | 'pre-dementia | 1 |
| 121 | 0-2.07 | 1 |
| 122 | 1-acenaphthenol | 1 |
| 123 | 10-20min | 1 |
| 124 | 100*r | 1 |
| 125 | 11-keto-metabolite | 1 |
| 126 | 11-site | 1 |
| 127 | 13,678 | 1 |
| 128 | 14:0-coa | 1 |
| 129 | 15-lox-1 | 1 |
| 130 | 15min/d | 1 |
| 131 | 15weeks | 1 |
| 132 | 165d | 1 |
| 133 | 16min | 1 |
| 134 | 1990-7/2002 | 1 |
| 135 | 1993/1996 | 1 |
| 136 | 2,5-dimethylphenyl | 1 |
| 137 | 2-benzyloxy-substituted | 1 |
| 138 | 2-ethoxymethyl-6-ethyl-2,3,4,5-tetrahydro-1,2,4-triazine-3,5-dione | 1 |
| 139 | 25.0-27.4 | 1 |
| 140 | 26,259 | 1 |
| 141 | 3,177 | 1 |
| 142 | 3,4,5,6-inositol | 1 |
| 143 | 3,6-anhydro- | 1 |
| 144 | 3-6weeks | 1 |
| 145 | 3-o-glycosyl | 1 |
| 146 | 37.3min | 1 |
| 147 | 4-estrendione | 1 |
| 148 | 4-substitution | 1 |
| 149 | 4.5weeks | 1 |
| 150 | 44days | 1 |
| 151 | 5-120min | 1 |
| 152 | 566+ | 1 |
| 153 | 6721961 | 1 |
| 154 | 78weeks | 1 |
| 155 | 8-center | 1 |
| 156 | 8-to-10-week | 1 |
| 157 | 810-bed | 1 |
| 158 | 82-week | 1 |
| 159 | 9°c- | 1 |
| 160 | a-apd | 1 |
| 161 | aaa-atpases | 1 |
| 162 | accessorial | 1 |
| 163 | acellularity | 1 |
| 164 | aching-syndromes | 1 |
| 165 | aci-reductone | 1 |
| 166 | active-curious | 1 |
| 167 | active-tdcs | 1 |
| 168 | actual-self | 1 |
| 169 | acupuncture-relevant | 1 |
| 170 | adjuvant-treatment | 1 |
| 171 | admninistration | 1 |
| 172 | agb4000 | 1 |
| 173 | agency-oriented | 1 |
| 174 | ahss | 1 |
| 175 | aian-run | 1 |
| 176 | aircraft/aerospace | 1 |
| 177 | aitc-lys | 1 |
| 178 | akt-foxo3a | 1 |
| 179 | albumin-rich | 1 |
| 180 | alkyne-terminated | 1 |
| 181 | allele*1 | 1 |
| 182 | allylbenzene | 1 |
| 183 | alphaviruses | 1 |
| 184 | amb-flu | 1 |
| 185 | amelioration/management | 1 |
| 186 | ameliorization | 1 |
| 187 | aminopyrimidine-based | 1 |
| 188 | amo2 | 1 |
| 189 | amplification/deletion | 1 |
| 190 | amylinomimetic | 1 |
| 191 | analysis.mothers | 1 |
| 192 | analysis.none | 1 |
| 193 | analysis.results | 1 |
| 194 | anesthesiologist-led | 1 |
| 195 | angle-correction | 1 |
| 196 | annoyance/agitation- | 1 |
| 197 | anti-catarrhal | 1 |
| 198 | anti-hyperglycemia | 1 |
| 199 | anticonvalsant | 1 |
| 200 | antihyperalgesia | 1 |
| 201 | antiplasticizer | 1 |
| 202 | antipsychotic.however | 1 |
| 203 | apiata | 1 |
| 204 | apolipoproteinb-synthesis-inhibitor | 1 |
| 205 | apri=0.810 | 1 |
| 206 | ar-antagonist | 1 |
| 207 | arginine-based-inhibitor | 1 |
| 208 | aromatherapist | 1 |
| 209 | arteriosonde | 1 |
| 210 | as-hf | 1 |
| 211 | aspirin-independent | 1 |
| 212 | aspongopusin | 1 |
| 213 | auc0-t. | 1 |
| 214 | aucinfo | 1 |
| 215 | avellaneum | 1 |
| 216 | avenaceus | 1 |
| 217 | ayana | 1 |
| 218 | azadiamidine | 1 |
| 219 | b-pa-z-c | 1 |
| 220 | b-z-c | 1 |
| 221 | be/eac | 1 |
| 222 | benignities | 1 |
| 223 | bio-functionalization | 1 |
| 224 | bioavailability/bioaccessibility | 1 |
| 225 | biotesting | 1 |
| 226 | bladha-1 | 1 |
| 227 | bmktt-1 | 1 |
| 228 | bmktt-2 | 1 |
| 229 | bmktt-3 | 1 |
| 230 | breast-feeding.comparisons | 1 |
| 231 | bulls- | 1 |
| 232 | bupropion-escitalopram | 1 |
| 233 | c2-functionalization | 1 |
| 234 | c22h26n4o2 | 1 |
| 235 | caldoxylosilyticus | 1 |
| 236 | calmette� | 1 |
| 237 | cancer-staging | 1 |
| 238 | carbamazepine/oxcarbazepine | 1 |
| 239 | cardialgic | 1 |
| 240 | cardioprophylaxis | 1 |
| 241 | catenin-d2 | 1 |
| 242 | cerebovascular | 1 |
| 243 | cf₃br.benzene | 1 |
| 244 | ch3ch2f | 1 |
| 245 | charge-diffuse | 1 |
| 246 | child-abuse | 1 |
| 247 | cholangitis-related | 1 |
| 248 | classification/discrimination | 1 |
| 249 | cleaning/decontamination | 1 |
| 250 | clearing-heat | 1 |
| 251 | cm.objective | 1 |
| 252 | co-colonisation | 1 |
| 253 | community-associated-uti | 1 |
| 254 | comparisons.none | 1 |
| 255 | consent/refusal | 1 |
| 256 | corcovado | 1 |
| 257 | coreana | 1 |
| 258 | cotrimozaxole | 1 |
| 259 | covarieties | 1 |
| 260 | crunches | 1 |
| 261 | cryptocaryosis | 1 |
| 262 | ct+t | 1 |
| 263 | cu-7 | 1 |
| 264 | cyp2c9*1/*2 | 1 |
| 265 | cyp2c9*2/*2 | 1 |
| 266 | cyp2c9*2/*3 | 1 |
| 267 | cys99ser | 1 |
| 268 | d'italia | 1 |
| 269 | d26 | 1 |
| 270 | d6-25-oh-d₃ | 1 |
| 271 | dacryostenosis | 1 |
| 272 | dalcochinin | 1 |
| 273 | dbp.trials | 1 |
| 274 | dbs-studies | 1 |
| 275 | death.it | 1 |
| 276 | death=1.04 | 1 |
| 277 | decoding/classification | 1 |
| 278 | dehumanized | 1 |
| 279 | demethylsertraline | 1 |
| 280 | demo-socio-economic | 1 |
| 281 | detection/screening | 1 |
| 282 | dfr2d | 1 |
| 283 | diety | 1 |
| 284 | diode-pumping | 1 |
| 285 | disinfestations | 1 |
| 286 | double-lesion | 1 |
| 287 | dtpa-hib-hbv | 1 |
| 288 | dune-fixation | 1 |
| 289 | e-mail-linked | 1 |
| 290 | e-runner | 1 |
| 291 | e/e'-picp | 1 |
| 292 | e/elateral | 1 |
| 293 | early-period | 1 |
| 294 | earlyonset | 1 |
| 295 | easy-to-collect | 1 |
| 296 | ebv-driven | 1 |
| 297 | eco-region | 1 |
| 298 | ectoenzyme | 1 |
| 299 | ectoenzymes | 1 |
| 300 | effect-modifier | 1 |
| 301 | effect=0.004 | 1 |
| 302 | efs-iris | 1 |
| 303 | egfrs≥90 | 1 |
| 304 | ehr-integrated | 1 |
| 305 | eight-core | 1 |
| 306 | eight-treatment | 1 |
| 307 | electromanometer | 1 |
| 308 | emancipating | 1 |
| 309 | enantiomorph | 1 |
| 310 | encoding-phase | 1 |
| 311 | endocytosis-requiring | 1 |
| 312 | endomyocarditis | 1 |
| 313 | endovascular-assisted | 1 |
| 314 | energy-mediated | 1 |
| 315 | entero/sigmoidocele | 1 |
| 316 | enteropathogenicity | 1 |
| 317 | entertainer | 1 |
| 318 | enumeration/identification | 1 |
| 319 | environment-centred | 1 |
| 320 | epipolythiopiperazine-2 | 1 |
| 321 | equerry | 1 |
| 322 | eriocarpa | 1 |
| 323 | eukoenenia | 1 |
| 324 | eva/stereospsis | 1 |
| 325 | evidence-based-albeit | 1 |
| 326 | evolutionary-conserved | 1 |
| 327 | ex-intimate | 1 |
| 328 | ex-olympic | 1 |
| 329 | extra-ventricular-device | 1 |
| 330 | extraction-fractionation | 1 |
| 331 | fact-btoi | 1 |
| 332 | failure/interruption | 1 |
| 333 | fc-mutated | 1 |
| 334 | feralization | 1 |
| 335 | fiagnosis | 1 |
| 336 | fibromyaligia | 1 |
| 337 | fischieri | 1 |
| 338 | fkbp-12 | 1 |
| 339 | flammna | 1 |
| 340 | flexion.coefficients | 1 |
| 341 | fluoxetine.overall | 1 |
| 342 | fomycin | 1 |
| 343 | fr- | 1 |
| 344 | full/postcard/full | 1 |
| 345 | functioning/qol | 1 |
| 346 | gemcitabine-platinum- | 1 |
| 347 | germinability | 1 |
| 348 | glutethimide | 1 |
| 349 | gog114 | 1 |
| 350 | gowlings | 1 |
| 351 | gtv-definition | 1 |
| 352 | h2-activation | 1 |
| 353 | haemoprotozoa | 1 |
| 354 | haemorrahage | 1 |
| 355 | hair-blacking | 1 |
| 356 | hepg2/c3a | 1 |
| 357 | high-utilizing | 1 |
| 358 | hist1h3b | 1 |
| 359 | hla-a*01 | 1 |
| 360 | hla-c2 | 1 |
| 361 | hna-1a | 1 |
| 362 | hna-1c | 1 |
| 363 | hna-4a | 1 |
| 364 | hna-4b | 1 |
| 365 | home/family | 1 |
| 366 | host-priming | 1 |
| 367 | hr0 | 1 |
| 368 | hr=3.50 | 1 |
| 369 | hui2/sf-6d | 1 |
| 370 | hui3/sf-6d | 1 |
| 371 | hybernum | 1 |
| 372 | hyperklemia | 1 |
| 373 | i-elements | 1 |
| 374 | icu-managed | 1 |
| 375 | ill-disciplined | 1 |
| 376 | immune-abnormal | 1 |
| 377 | immunomodifier | 1 |
| 378 | impairment-oriented | 1 |
| 379 | imperiosity | 1 |
| 380 | incident-driven | 1 |
| 381 | individual-threat | 1 |
| 382 | indole-2-s-glycosides | 1 |
| 383 | iniquitous | 1 |
| 384 | intact-side | 1 |
| 385 | intance | 1 |
| 386 | intermodal/intersubject | 1 |
| 387 | intradural-enhancing | 1 |
| 388 | irvo | 1 |
| 389 | iso-ventilation | 1 |
| 390 | isopropylidene-protected | 1 |
| 391 | itsclinical | 1 |
| 392 | j60- | 1 |
| 393 | kashmirensis | 1 |
| 394 | kinesiophobia-version | 1 |
| 395 | klinske | 1 |
| 396 | kolaensis | 1 |
| 397 | kouter | 1 |
| 398 | krasc.146 | 1 |
| 399 | krasnovskaya | 1 |
| 400 | kwangtungensis | 1 |
| 401 | l101 | 1 |
| 402 | lasiopus | 1 |
| 403 | lcnecs | 1 |
| 404 | ldl-apheresis/haemorheopheresis | 1 |
| 405 | lipophagy | 1 |
| 406 | litholysis | 1 |
| 407 | lmktt-1b | 1 |
| 408 | lmktt-1c | 1 |
| 409 | low-channel-count | 1 |
| 410 | lrh-a | 1 |
| 411 | luts-bpe | 1 |
| 412 | lv-edvi | 1 |
| 413 | lying/sitting | 1 |
| 414 | lysodeikticus | 1 |
| 415 | læger | 1 |
| 416 | mat1a | 1 |
| 417 | mbsr-experts | 1 |
| 418 | mdi/mdl-aii | 1 |
| 419 | mefloquine/artesunate | 1 |
| 420 | memory/independence | 1 |
| 421 | meth-dependence | 1 |
| 422 | metronidazole+clarithromycin | 1 |
| 423 | mf.bac | 1 |
| 424 | mfgm-supplemented | 1 |
| 425 | mir-371b-3p | 1 |
| 426 | mjl1-109-2 | 1 |
| 427 | mpr/3d | 1 |
| 428 | mri-investigation | 1 |
| 429 | mtsb | 1 |
| 430 | muc16/tn | 1 |
| 431 | mucilaginosus | 1 |
| 432 | multi-causality | 1 |
| 433 | mutual-supplementing | 1 |
| 434 | n-glucoside | 1 |
| 435 | n-hydroxysulfenamide | 1 |
| 436 | n-isobutylamide | 1 |
| 437 | nanoneuroprotection | 1 |
| 438 | ndufs3 | 1 |
| 439 | nefrología | 1 |
| 440 | new-quinolone | 1 |
| 441 | nl33995.060.10 | 1 |
| 442 | non-ccrccs | 1 |
| 443 | non-elucidation | 1 |
| 444 | non-lbw | 1 |
| 445 | non-normalization | 1 |
| 446 | non-transitioners | 1 |
| 447 | noncomparability | 1 |
| 448 | nongeneralizability | 1 |
| 449 | noninferiority=0.03 | 1 |
| 450 | nonuptake | 1 |
| 451 | nsag2 | 1 |
| 452 | oat-biomarker | 1 |
| 453 | octylcyanocrylate | 1 |
| 454 | ocufilm-fingertip | 1 |
| 455 | oncobiomarker | 1 |
| 456 | online-experiment | 1 |
| 457 | open-plan | 1 |
| 458 | opg-associated | 1 |
| 459 | optiscope | 1 |
| 460 | opz/oh-opz/opz-sfn | 1 |
| 461 | ordeals | 1 |
| 462 | orientation/mood | 1 |
| 463 | os=2.60 | 1 |
| 464 | ospr4e | 1 |
| 465 | otopathy | 1 |
| 466 | out-building | 1 |
| 467 | out-docking-mode | 1 |
| 468 | overgenerality | 1 |
| 469 | ovine-derived | 1 |
| 470 | ovo-lacto-vegetarians | 1 |
| 471 | ovoid-shaped | 1 |
| 472 | oxo-rich | 1 |
| 473 | p-ct. | 1 |
| 474 | p-diary | 1 |
| 475 | p-elements | 1 |
| 476 | paclitaxel+carboplatin | 1 |
| 477 | participants.none | 1 |
| 478 | patient/proxy | 1 |
| 479 | pbsch | 1 |
| 480 | pcb169 | 1 |
| 481 | pcv13/ppsv23/pcv13 | 1 |
| 482 | pelfgroup-1 | 1 |
| 483 | ph/pah | 1 |
| 484 | phospho-motifs | 1 |
| 485 | photo-induction | 1 |
| 486 | pinkeye | 1 |
| 487 | platinum-anthracycline | 1 |
| 488 | plf+fs | 1 |
| 489 | pltxs | 1 |
| 490 | poot | 1 |
| 491 | pr-relapse | 1 |
| 492 | practice/conclusion | 1 |
| 493 | pre-bp | 1 |
| 494 | prediction/prevention | 1 |
| 495 | prefrailty | 1 |
| 496 | presence/extent | 1 |
| 497 | prevention/control | 1 |
| 498 | primer/vitremer | 1 |
| 499 | pro-hormones | 1 |
| 500 | progression=1.18 | 1 |
| 501 | pseudophedrine | 1 |
| 502 | q=10 | 1 |
| 503 | quality/risk | 1 |
| 504 | quercetorum | 1 |
| 505 | rat8p/dbp5p | 1 |
| 506 | re-priming | 1 |
| 507 | re-ratings | 1 |
| 508 | re-vegetation | 1 |
| 509 | refolding/disaggregation | 1 |
| 510 | regrasp | 1 |
| 511 | resistance/survival | 1 |
| 512 | resistant-plasmodia | 1 |
| 513 | restration | 1 |
| 514 | rheumatitis | 1 |
| 515 | rhinoplasty/septoplasty | 1 |
| 516 | rhythmologists | 1 |
| 517 | rosucastatin | 1 |
| 518 | rs10752979 | 1 |
| 519 | rs1203633 | 1 |
| 520 | rs1799971*g | 1 |
| 521 | rs3135005 | 1 |
| 522 | rs4648310 | 1 |
| 523 | rtms-first-sham-second | 1 |
| 524 | ruffell | 1 |
| 525 | sanitisation | 1 |
| 526 | sarcopenia/dynapenia | 1 |
| 527 | schistosmiasis | 1 |
| 528 | schwann/2e | 1 |
| 529 | self-adaptive | 1 |
| 530 | self-regulation® | 1 |
| 531 | shoulder-axillary | 1 |
| 532 | sick/ill | 1 |
| 533 | sinkiangensis | 1 |
| 534 | sinustitis | 1 |
| 535 | sixmonths | 1 |
| 536 | slips/trips/falls | 1 |
| 537 | slsmax | 1 |
| 538 | soils/shales | 1 |
| 539 | sp.. | 1 |
| 540 | spb-octyl | 1 |
| 541 | spironolactone-ace | 1 |
| 542 | staphlococcal | 1 |
| 543 | stearothermophilus-based | 1 |
| 544 | strategic/commercial | 1 |
| 545 | studing | 1 |
| 546 | suitableness | 1 |
| 547 | sulfadoxine/pyrimethamine-artesunate | 1 |
| 548 | sulfafurazol | 1 |
| 549 | sweetgum | 1 |
| 550 | syncercid | 1 |
| 551 | syringing.none | 1 |
| 552 | systolic-sr | 1 |
| 553 | t-stages | 1 |
| 554 | t2/pre-contrast | 1 |
| 555 | tapse/bsa | 1 |
| 556 | terrestrially | 1 |
| 557 | tetra-hexabdes | 1 |
| 558 | thermo-targeting | 1 |
| 559 | thermocarboxydus | 1 |
| 560 | thisdouble-blind | 1 |
| 561 | tigecycline-colistin | 1 |
| 562 | timesteps | 1 |
| 563 | titrivin | 1 |
| 564 | tm-e180g | 1 |
| 565 | transformability | 1 |
| 566 | traumatology/orthopaedics | 1 |
| 567 | trend=3.833 | 1 |
| 568 | trichomonal+bacterial | 1 |
| 569 | trichomonal-only | 1 |
| 570 | trinorsesquiterpenoids | 1 |
| 571 | ttr=2.52 | 1 |
| 572 | tvr-lead-in-rr | 1 |
| 573 | tvr-par | 1 |
| 574 | undergirding | 1 |
| 575 | unspeeded | 1 |
| 576 | urocytogram | 1 |
| 577 | use/repairs | 1 |
| 578 | usssi | 1 |
| 579 | valatanib | 1 |
| 580 | vas/wes | 1 |
| 581 | venovenostomy | 1 |
| 582 | vps60 | 1 |
| 583 | vuralii | 1 |
| 584 | windows® | 1 |
| 585 | wittichii | 1 |
| 586 | woman-controlled | 1 |
| 587 | wulii | 1 |
| 588 | wup0 | 1 |
| 589 | yabgn | 1 |
| 590 | year-season | 1 |
| 591 | years/lifetime | 1 |
| 592 | yoolmok | 1 |
| 593 | yz-pt | 1 |
| 594 | zb-crn | 1 |
| 595 | znco3 | 1 |
| 596 | «major | 1 |
| 597 | α-copaene/δ-cadinene | 1 |
| 598 | α-eudesmol | 1 |
| 599 | α-l-rhamnopyrannosyl | 1 |
| 600 | α-methyl-coa-racemase | 1 |
| 601 | α4*-nachr | 1 |
| 602 | β-1,3-linkage | 1 |
| 603 | β-1,6-galactooligosaccharides | 1 |
| 604 | μ=2 | 1 |
| 605 | ∑pahs | 1 |
| 606 | ≤12h | 1 |
| 607 | ≤74/≥75 | 1 |
| 1 | 'pre-dementia | 1 |
| 2 | -accuracy | 2 |
| 3 | 0-2.07 | 1 |
| 4 | 1-acenaphthenol | 1 |
| 5 | 10-20min | 1 |
| 6 | 100*r | 1 |
| 7 | 11-keto-metabolite | 1 |
| 8 | 11-site | 1 |
| 9 | 13,678 | 1 |
| 10 | 14:0-coa | 1 |
| 11 | 15-lox-1 | 1 |
| 12 | 15min/d | 1 |
| 13 | 15weeks | 1 |
| 14 | 165d | 1 |
| 15 | 16min | 1 |
| 16 | 1990-7/2002 | 1 |
| 17 | 1993/1996 | 1 |
| 18 | 1xh5n1-as | 5 |
| 19 | 2,5-dimethylphenyl | 1 |
| 20 | 2-benzyloxy-substituted | 1 |
| 21 | 2-ethoxymethyl-6-ethyl-2,3,4,5-tetrahydro-1,2,4-triazine-3,5-dione | 1 |
| 22 | 25.0-27.4 | 1 |
| 23 | 26,259 | 1 |
| 24 | 2xh5n1-as | 5 |
| 25 | 3,177 | 1 |
| 26 | 3,4,5,6-inositol | 1 |
| 27 | 3,6-anhydro- | 1 |
| 28 | 3-6weeks | 1 |
| 29 | 3-o-glycosyl | 1 |
| 30 | 30min/d | 2 |
| 31 | 37.3min | 1 |
| 32 | 4-estrendione | 1 |
| 33 | 4-substitution | 1 |
| 34 | 4.5weeks | 1 |
| 35 | 44days | 1 |
| 36 | 5-120min | 1 |
| 37 | 5-dsf | 2 |
| 38 | 515-3p | 2 |
| 39 | 517a | 2 |
| 40 | 517c | 2 |
| 41 | 566+ | 1 |
| 42 | 6-dsf | 2 |
| 43 | 6721961 | 1 |
| 44 | 78weeks | 1 |
| 45 | 8-center | 1 |
| 46 | 8-to-10-week | 1 |
| 47 | 810-bed | 1 |
| 48 | 82-week | 1 |
| 49 | 9°c- | 1 |
| 50 | a-apd | 1 |
| 51 | aaa-atpases | 1 |
| 52 | accessorial | 1 |
| 53 | acellularity | 1 |
| 54 | aching-syndromes | 1 |
| 55 | aci-reductone | 1 |
| 56 | acri/arb | 2 |
| 57 | active-curious | 1 |
| 58 | active-tdcs | 1 |
| 59 | actual-self | 1 |
| 60 | acupuncture-relevant | 1 |
| 61 | adjuvant-treatment | 1 |
| 62 | admninistration | 1 |
| 63 | agb4000 | 1 |
| 64 | age-homogenous | 2 |
| 65 | agency-oriented | 1 |
| 66 | ahss | 1 |
| 67 | aian-run | 1 |
| 68 | aircraft/aerospace | 1 |
| 69 | aitc-lys | 1 |
| 70 | akt-foxo3a | 1 |
| 71 | albumin-rich | 1 |
| 72 | alkyne-terminated | 1 |
| 73 | allele*1 | 1 |
| 74 | allylbenzene | 1 |
| 75 | alphaviruses | 1 |
| 76 | alwa | 4 |
| 77 | amb-flu | 1 |
| 78 | ambar/fsp | 2 |
| 79 | amelioration/management | 1 |
| 80 | ameliorization | 1 |
| 81 | aminopyrimidine-based | 1 |
| 82 | amo2 | 1 |
| 83 | amplification/deletion | 1 |
| 84 | amylinomimetic | 1 |
| 85 | analysis.mothers | 1 |
| 86 | analysis.none | 1 |
| 87 | analysis.results | 1 |
| 88 | anesthesiologist-led | 1 |
| 89 | angle-correction | 1 |
| 90 | angora-cont | 2 |
| 91 | annoyance/agitation- | 1 |
| 92 | antedrugs | 2 |
| 93 | anti-catarrhal | 1 |
| 94 | anti-hyperglycemia | 1 |
| 95 | anticonvalsant | 1 |
| 96 | antihyperalgesia | 1 |
| 97 | antiplasticizer | 1 |
| 98 | antiprogestogen | 3 |
| 99 | antipsychotic.however | 1 |
| 100 | apiata | 1 |
| 101 | apolipoproteinb-synthesis-inhibitor | 1 |
| 102 | apri=0.810 | 1 |
| 103 | ar-antagonist | 1 |
| 104 | arginine-based-inhibitor | 1 |
| 105 | aromatherapist | 1 |
| 106 | arteriosonde | 1 |
| 107 | as-hf | 1 |
| 108 | aspirin-independent | 1 |
| 109 | aspongopusin | 1 |
| 110 | auc0-t. | 1 |
| 111 | aucinfo | 1 |
| 112 | avellaneum | 1 |
| 113 | avenaceus | 1 |
| 114 | ayana | 1 |
| 115 | azadiamidine | 1 |
| 116 | b-pa-z-c | 1 |
| 117 | b-z-c | 1 |
| 118 | be/eac | 1 |
| 119 | benignities | 1 |
| 120 | benzene-acetylene | 2 |
| 121 | benzyl-itc | 2 |
| 122 | bio-fuels | 2 |
| 123 | bio-functionalization | 1 |
| 124 | bioavailability/bioaccessibility | 1 |
| 125 | biotesting | 1 |
| 126 | bladha-1 | 1 |
| 127 | bmktt-1 | 1 |
| 128 | bmktt-2 | 1 |
| 129 | bmktt-3 | 1 |
| 130 | breast-feeding.comparisons | 1 |
| 131 | bulls- | 1 |
| 132 | bupropion-escitalopram | 1 |
| 133 | c2-functionalization | 1 |
| 134 | c22h26n4o2 | 1 |
| 135 | caldoxylosilyticus | 1 |
| 136 | calmette� | 1 |
| 137 | cancer-staging | 1 |
| 138 | carbamazepine/oxcarbazepine | 1 |
| 139 | cardialgic | 1 |
| 140 | cardioprophylaxis | 1 |
| 141 | catenin-d2 | 1 |
| 142 | cerebovascular | 1 |
| 143 | cf₃br.benzene | 1 |
| 144 | ch3ch2f | 1 |
| 145 | charge-diffuse | 1 |
| 146 | child-abuse | 1 |
| 147 | children-2 | 5 |
| 148 | children-iii | 3 |
| 149 | children-revised | 11 |
| 150 | cholangitis-related | 1 |
| 151 | classification/discrimination | 1 |
| 152 | cleaning/decontamination | 1 |
| 153 | clearing-heat | 1 |
| 154 | cm.objective | 1 |
| 155 | co-colonisation | 1 |
| 156 | community-associated-uti | 1 |
| 157 | comparisons.none | 1 |
| 158 | consent/refusal | 1 |
| 159 | content/quantity | 2 |
| 160 | copmi-children | 3 |
| 161 | corcovado | 1 |
| 162 | coreana | 1 |
| 163 | cotrimozaxole | 1 |
| 164 | covarieties | 1 |
| 165 | co₂tisn | 2 |
| 166 | crunches | 1 |
| 167 | cryptocaryosis | 1 |
| 168 | ct+t | 1 |
| 169 | ct-imaging | 2 |
| 170 | cu-7 | 1 |
| 171 | cyp2a61b | 2 |
| 172 | cyp2c9*1/*2 | 1 |
| 173 | cyp2c9*2/*2 | 1 |
| 174 | cyp2c9*2/*3 | 1 |
| 175 | cys99ser | 1 |
| 176 | d'italia | 1 |
| 177 | d26 | 1 |
| 178 | d6-25-oh-d₃ | 1 |
| 179 | dacryostenosis | 1 |
| 180 | dalcochinin | 1 |
| 181 | data-sets | 2 |
| 182 | day-matched | 2 |
| 183 | dbp.trials | 1 |
| 184 | dbs-studies | 1 |
| 185 | death.it | 1 |
| 186 | death=1.04 | 1 |
| 187 | decoding/classification | 1 |
| 188 | deed | 2 |
| 189 | dehumanized | 1 |
| 190 | demethylsertraline | 1 |
| 191 | demo-socio-economic | 1 |
| 192 | detection/screening | 1 |
| 193 | dfr2d | 1 |
| 194 | diety | 1 |
| 195 | diode-pumping | 1 |
| 196 | disinfestations | 1 |
| 197 | distilisation | 2 |
| 198 | dose/mass | 3 |
| 199 | double-lesion | 1 |
| 200 | dtpa-hib-hbv | 1 |
| 201 | dune-fixation | 1 |
| 202 | e-mail-linked | 1 |
| 203 | e-runner | 1 |
| 204 | e/e'-picp | 1 |
| 205 | e/elateral | 1 |
| 206 | early-period | 1 |
| 207 | earlyonset | 1 |
| 208 | easy-to-collect | 1 |
| 209 | ebv-driven | 1 |
| 210 | eco-region | 1 |
| 211 | ectoenzyme | 1 |
| 212 | ectoenzymes | 1 |
| 213 | effect-modifier | 1 |
| 214 | effect=0.004 | 1 |
| 215 | efs-iris | 1 |
| 216 | egfrs≥90 | 1 |
| 217 | ehr-integrated | 1 |
| 218 | eight-core | 1 |
| 219 | eight-treatment | 1 |
| 220 | electromanometer | 1 |
| 221 | emancipating | 1 |
| 222 | enantiomorph | 1 |
| 223 | encapsulant | 4 |
| 224 | encoding-phase | 1 |
| 225 | endo-inulinase | 2 |
| 226 | endocytosis-requiring | 1 |
| 227 | endomyocarditis | 1 |
| 228 | endovascular-assisted | 1 |
| 229 | energy-mediated | 1 |
| 230 | entero/sigmoidocele | 1 |
| 231 | enteropathogenicity | 1 |
| 232 | entertainer | 1 |
| 233 | enumeration/identification | 1 |
| 234 | environment-centred | 1 |
| 235 | epipolythiopiperazine-2 | 1 |
| 236 | equerry | 1 |
| 237 | ergonomist | 3 |
| 238 | eriocarpa | 1 |
| 239 | eukoenenia | 1 |
| 240 | eva/stereospsis | 1 |
| 241 | ever-symptoms | 2 |
| 242 | evidence-based-albeit | 1 |
| 243 | evolutionary-conserved | 1 |
| 244 | ex-intimate | 1 |
| 245 | ex-olympic | 1 |
| 246 | example | 4,235 |
| 247 | extra-ventricular-device | 1 |
| 248 | extraction-fractionation | 1 |
| 249 | fact-btoi | 1 |
| 250 | failure/interruption | 1 |
| 251 | fat/water | 2 |
| 252 | fc-mutated | 1 |
| 253 | feralization | 1 |
| 254 | fiagnosis | 1 |
| 255 | fibromyaligia | 1 |
| 256 | fischieri | 1 |
| 257 | fkbp-12 | 1 |
| 258 | flammna | 1 |
| 259 | flexion.coefficients | 1 |
| 260 | fluoxetine.overall | 1 |
| 261 | fne48 | 2 |
| 262 | fomycin | 1 |
| 263 | four-days | 2 |
| 264 | fr- | 1 |
| 265 | full/postcard/full | 1 |
| 266 | functioning/qol | 1 |
| 267 | gemcitabine-platinum- | 1 |
| 268 | germinability | 1 |
| 269 | glutelins | 3 |
| 270 | glutethimide | 1 |
| 271 | gog114 | 1 |
| 272 | gowlings | 1 |
| 273 | granulosum | 2 |
| 274 | gtv-definition | 1 |
| 275 | h1-blocker | 2 |
| 276 | h1a | 6 |
| 277 | h2-activation | 1 |
| 278 | haemoprotozoa | 1 |
| 279 | haemorrahage | 1 |
| 280 | hair-blacking | 1 |
| 281 | hazardless | 2 |
| 282 | hepg2/c3a | 1 |
| 283 | high-utilizing | 1 |
| 284 | hist1h3b | 1 |
| 285 | hitters | 3 |
| 286 | hla-a*01 | 1 |
| 287 | hla-c2 | 1 |
| 288 | hna-1a | 1 |
| 289 | hna-1c | 1 |
| 290 | hna-4a | 1 |
| 291 | hna-4b | 1 |
| 292 | home/family | 1 |
| 293 | host-priming | 1 |
| 294 | hpv-59 | 3 |
| 295 | hr0 | 1 |
| 296 | hr=3.50 | 1 |
| 297 | hui2/sf-6d | 1 |
| 298 | hui3/sf-6d | 1 |
| 299 | hybernum | 1 |
| 300 | hyperklemia | 1 |
| 301 | i-elements | 1 |
| 302 | i.n. | 3 |
| 303 | icu-managed | 1 |
| 304 | ill-disciplined | 1 |
| 305 | illustration | 154 |
| 306 | immune-abnormal | 1 |
| 307 | immunomodifier | 1 |
| 308 | impairment-oriented | 1 |
| 309 | imperiosity | 1 |
| 310 | incana | 2 |
| 311 | incident-driven | 1 |
| 312 | individual-threat | 1 |
| 313 | indole-2-s-glycosides | 1 |
| 314 | iniquitous | 1 |
| 315 | instance | 587 |
| 316 | intact-side | 1 |
| 317 | intance | 1 |
| 318 | interaction=0.01 | 2 |
| 319 | intermodal/intersubject | 1 |
| 320 | intradural-enhancing | 1 |
| 321 | irvo | 1 |
| 322 | iso-ventilation | 1 |
| 323 | isopropylidene-protected | 1 |
| 324 | itsclinical | 1 |
| 325 | j60- | 1 |
| 326 | j84.1 | 2 |
| 327 | kashmirensis | 1 |
| 328 | khuzestanica | 2 |
| 329 | kinesiophobia-version | 1 |
| 330 | kliniske | 19 |
| 331 | klinske | 1 |
| 332 | kolaensis | 1 |
| 333 | kouter | 1 |
| 334 | krasc.146 | 1 |
| 335 | krasnovskaya | 1 |
| 336 | kwangtungensis | 1 |
| 337 | l101 | 1 |
| 338 | lactation/kg | 2 |
| 339 | lasiopus | 1 |
| 340 | latreille | 8 |
| 341 | lcnecs | 1 |
| 342 | ldl-apheresis/haemorheopheresis | 1 |
| 343 | lipophagy | 1 |
| 344 | litholysis | 1 |
| 345 | lmktt-1b | 1 |
| 346 | lmktt-1c | 1 |
| 347 | lns-10gm | 2 |
| 348 | lns-20gnom | 2 |
| 349 | longituba | 2 |
| 350 | loss-from-care | 3 |
| 351 | low-channel-count | 1 |
| 352 | lps-cadmium | 2 |
| 353 | lrh-a | 1 |
| 354 | luts-bpe | 1 |
| 355 | lv-edvi | 1 |
| 356 | lying/sitting | 1 |
| 357 | lysodeikticus | 1 |
| 358 | læger | 1 |
| 359 | mat1a | 1 |
| 360 | mbsr-experts | 1 |
| 361 | mdi/mdl-aii | 1 |
| 362 | mefloquine/artesunate | 1 |
| 363 | memory/independence | 1 |
| 364 | meth-dependence | 1 |
| 365 | metronidazole+clarithromycin | 1 |
| 366 | mezlocillin/sulbactam | 2 |
| 367 | mf.bac | 1 |
| 368 | mfgm-supplemented | 1 |
| 369 | mir-371b-3p | 1 |
| 370 | mirabilis.recent | 2 |
| 371 | mjl1-109-2 | 1 |
| 372 | mpr/3d | 1 |
| 373 | mri-investigation | 1 |
| 374 | mtsb | 1 |
| 375 | muc16/tn | 1 |
| 376 | mucilaginosus | 1 |
| 377 | multi-causality | 1 |
| 378 | mutual-supplementing | 1 |
| 379 | n-glucoside | 1 |
| 380 | n-hydroxysulfenamide | 1 |
| 381 | n-isobutylamide | 1 |
| 382 | nano-pcpdtbse | 2 |
| 383 | nano-pcpdtbt | 2 |
| 384 | nanolization | 2 |
| 385 | nanoneuroprotection | 1 |
| 386 | ndufs3 | 1 |
| 387 | needle-less | 2 |
| 388 | nefrología | 1 |
| 389 | nephroureterctomy | 2 |
| 390 | new-quinolone | 1 |
| 391 | ng.hr/ml | 5 |
| 392 | nl33995.060.10 | 1 |
| 393 | non-ccrccs | 1 |
| 394 | non-elucidation | 1 |
| 395 | non-lbw | 1 |
| 396 | non-normalization | 1 |
| 397 | non-registration | 3 |
| 398 | non-transitioners | 1 |
| 399 | nonabuse | 4 |
| 400 | noncomparability | 1 |
| 401 | nongeneralizability | 1 |
| 402 | noninferiority=0.03 | 1 |
| 403 | nonuptake | 1 |
| 404 | nsag2 | 1 |
| 405 | oat-biomarker | 1 |
| 406 | octa-decabdes | 2 |
| 407 | octylcyanocrylate | 1 |
| 408 | ocufilm-fingertip | 1 |
| 409 | oncobiomarker | 1 |
| 410 | online-experiment | 1 |
| 411 | open-plan | 1 |
| 412 | opg-associated | 1 |
| 413 | optiscope | 1 |
| 414 | opz/oh-opz/opz-sfn | 1 |
| 415 | orally-active | 7 |
| 416 | ordeals | 1 |
| 417 | orientation/mood | 1 |
| 418 | os=2.60 | 1 |
| 419 | ospr4e | 1 |
| 420 | otopathy | 1 |
| 421 | out-building | 1 |
| 422 | out-docking-mode | 1 |
| 423 | overgenerality | 1 |
| 424 | ovine-derived | 1 |
| 425 | ovo-lacto-vegetarians | 1 |
| 426 | ovoid-shaped | 1 |
| 427 | oxo-rich | 1 |
| 428 | p-ct. | 1 |
| 429 | p-diary | 1 |
| 430 | p-elements | 1 |
| 431 | paclitaxel+carboplatin | 1 |
| 432 | pain/anxiety | 2 |
| 433 | pandolfi | 2 |
| 434 | panniculectomy/abdominoplasty | 3 |
| 435 | parallel-beam | 2 |
| 436 | participants.none | 1 |
| 437 | pathotype | 10 |
| 438 | patient/proxy | 1 |
| 439 | pbsch | 1 |
| 440 | pcb169 | 1 |
| 441 | pcv13/ppsv23/pcv13 | 1 |
| 442 | pelfgroup-1 | 1 |
| 443 | pemetrexed-carboplatin-enzastaurin | 2 |
| 444 | pennsylvanians | 2 |
| 445 | periodicals | 220 |
| 446 | permp-a | 2 |
| 447 | ph/pah | 1 |
| 448 | phospho-motifs | 1 |
| 449 | photo-induction | 1 |
| 450 | photorejuvenation | 4 |
| 451 | pinkeye | 1 |
| 452 | piperacillin/sulbactam | 2 |
| 453 | platinum-anthracycline | 1 |
| 454 | plf+fs | 1 |
| 455 | pltxs | 1 |
| 456 | poot | 1 |
| 457 | pr-relapse | 1 |
| 458 | practice/conclusion | 1 |
| 459 | pre-1990 | 4 |
| 460 | pre-bp | 1 |
| 461 | pre-coagulation | 2 |
| 462 | prediction/prevention | 1 |
| 463 | prefrailty | 1 |
| 464 | presence/extent | 1 |
| 465 | prevention/control | 1 |
| 466 | primer/vitremer | 1 |
| 467 | pro-hormones | 1 |
| 468 | progression=1.18 | 1 |
| 469 | proximus | 2 |
| 470 | pseudophedrine | 1 |
| 471 | pten/pi-3k | 2 |
| 472 | puerperant | 2 |
| 473 | q=10 | 1 |
| 474 | quality/risk | 1 |
| 475 | quercetorum | 1 |
| 476 | rat8p/dbp5p | 1 |
| 477 | re-impregnation | 2 |
| 478 | re-priming | 1 |
| 479 | re-ratings | 1 |
| 480 | re-vegetation | 1 |
| 481 | refolding/disaggregation | 1 |
| 482 | regrasp | 1 |
| 483 | researchthere | 2 |
| 484 | resistance/survival | 1 |
| 485 | resistant-plasmodia | 1 |
| 486 | restration | 1 |
| 487 | retweets | 3 |
| 488 | revision-augmentation | 4 |
| 489 | rheumatitis | 1 |
| 490 | rhinoplasty/septoplasty | 1 |
| 491 | rhythmologists | 1 |
| 492 | rosucastatin | 1 |
| 493 | rs-scn | 2 |
| 494 | rs10752979 | 1 |
| 495 | rs1203633 | 1 |
| 496 | rs1799971*g | 1 |
| 497 | rs274622 | 2 |
| 498 | rs3135005 | 1 |
| 499 | rs4648310 | 1 |
| 500 | rs588765 | 3 |
| 501 | rtms-first-sham-second | 1 |
| 502 | ruffell | 1 |
| 503 | s-h | 5 |
| 504 | sanitisation | 1 |
| 505 | sarcopenia/dynapenia | 1 |
| 506 | schistosmiasis | 1 |
| 507 | schwann/2e | 1 |
| 508 | sdhb | 2 |
| 509 | self-adaptive | 1 |
| 510 | self-regulation® | 1 |
| 511 | shoulder-axillary | 1 |
| 512 | sick/ill | 1 |
| 513 | sinkiangensis | 1 |
| 514 | sinustitis | 1 |
| 515 | sixmonths | 1 |
| 516 | slips/trips/falls | 1 |
| 517 | slsmax | 1 |
| 518 | soils/shales | 1 |
| 519 | sp. | 241 |
| 520 | sp.. | 1 |
| 521 | spassky | 2 |
| 522 | spb-octyl | 1 |
| 523 | spectrophotometrical | 2 |
| 524 | spf24nae | 4 |
| 525 | spironolactone-ace | 1 |
| 526 | spp. | 513 |
| 527 | staphlococcal | 1 |
| 528 | stearothermophilus-based | 1 |
| 529 | strain/strength | 4 |
| 530 | strategic/commercial | 1 |
| 531 | stst-opt | 2 |
| 532 | studing | 1 |
| 533 | suitableness | 1 |
| 534 | sulfadoxine/pyrimethamine-artesunate | 1 |
| 535 | sulfafurazol | 1 |
| 536 | sweetgum | 1 |
| 537 | syncercid | 1 |
| 538 | syringing.none | 1 |
| 539 | systolic-sr | 1 |
| 540 | t-stages | 1 |
| 541 | t2/pre-contrast | 1 |
| 542 | tapse/bsa | 1 |
| 543 | tegobuvir/gs-9256 | 2 |
| 544 | tegobuvir/gs-9256/rbv | 2 |
| 545 | terbogrel | 2 |
| 546 | terrestrially | 1 |
| 547 | tetanus-toxoid | 6 |
| 548 | tetra-hexabdes | 1 |
| 549 | thermo-targeting | 1 |
| 550 | thermocarboxydus | 1 |
| 551 | thisdouble-blind | 1 |
| 552 | thorell | 2 |
| 553 | tigecycline-colistin | 1 |
| 554 | timesteps | 1 |
| 555 | titrivin | 1 |
| 556 | tm-e180g | 1 |
| 557 | transformability | 1 |
| 558 | transport-i | 2 |
| 559 | traumatology/orthopaedics | 1 |
| 560 | trend=0.012 | 2 |
| 561 | trend=3.833 | 1 |
| 562 | trichomonal+bacterial | 1 |
| 563 | trichomonal-only | 1 |
| 564 | tricyanofluoroborate | 2 |
| 565 | trinorsesquiterpenoids | 1 |
| 566 | ttr=2.52 | 1 |
| 567 | tvr-lead-in-rr | 1 |
| 568 | tvr-par | 1 |
| 569 | undergirding | 1 |
| 570 | unspeeded | 1 |
| 571 | urocytogram | 1 |
| 572 | use/repairs | 1 |
| 573 | usssi | 1 |
| 574 | valatanib | 1 |
| 575 | vas/wes | 1 |
| 576 | venlafaxine-mirtazapine | 2 |
| 577 | venovenostomy | 1 |
| 578 | video-only | 4 |
| 579 | vps60 | 1 |
| 580 | vuralii | 1 |
| 581 | windows® | 1 |
| 582 | wittichii | 1 |
| 583 | woman-controlled | 1 |
| 584 | wulii | 1 |
| 585 | wup0 | 1 |
| 586 | yabgn | 1 |
| 587 | year-season | 1 |
| 588 | years/lifetime | 1 |
| 589 | yhl-i | 3 |
| 590 | yoolmok | 1 |
| 591 | yz-pt | 1 |
| 592 | z907 | 2 |
| 593 | zb-crn | 1 |
| 594 | znco3 | 1 |
| 595 | «major | 1 |
| 596 | α-copaene/δ-cadinene | 1 |
| 597 | α-eudesmol | 1 |
| 598 | α-l-rhamnopyrannosyl | 1 |
| 599 | α-methyl-coa-racemase | 1 |
| 600 | α4*-nachr | 1 |
| 601 | β-1,3-linkage | 1 |
| 602 | β-1,6-galactooligosaccharides | 1 |
| 603 | δ6-elongase | 2 |
| 604 | μ=2 | 1 |
| 605 | ∑pahs | 1 |
| 606 | ≤12h | 1 |
| 607 | ≤74/≥75 | 1 |
| 1 | 566+ | 1 |
| 2 | j60- | 1 |
| 3 | 9°c- | 1 |
| 4 | gemcitabine-platinum- | 1 |
| 5 | annoyance/agitation- | 1 |
| 6 | 3,6-anhydro- | 1 |
| 7 | fr- | 1 |
| 8 | bulls- | 1 |
| 9 | sp.. | 1 |
| 10 | i.n. | 3 |
| 11 | spp. | 513 |
| 12 | sp. | 241 |
| 13 | auc0-t. | 1 |
| 14 | p-ct. | 1 |
| 15 | agb4000 | 1 |
| 16 | nl33995.060.10 | 1 |
| 17 | rs4648310 | 1 |
| 18 | apri=0.810 | 1 |
| 19 | q=10 | 1 |
| 20 | hr=3.50 | 1 |
| 21 | os=2.60 | 1 |
| 22 | vps60 | 1 |
| 23 | pre-1990 | 4 |
| 24 | egfrs≥90 | 1 |
| 25 | wup0 | 1 |
| 26 | hr0 | 1 |
| 27 | allele*1 | 1 |
| 28 | bladha-1 | 1 |
| 29 | pelfgroup-1 | 1 |
| 30 | bmktt-1 | 1 |
| 31 | 15-lox-1 | 1 |
| 32 | j84.1 | 2 |
| 33 | hla-a*01 | 1 |
| 34 | interaction=0.01 | 2 |
| 35 | l101 | 1 |
| 36 | 6721961 | 1 |
| 37 | cyp2c9*1/*2 | 1 |
| 38 | cyp2c9*2/*2 | 1 |
| 39 | mjl1-109-2 | 1 |
| 40 | epipolythiopiperazine-2 | 1 |
| 41 | children-2 | 5 |
| 42 | bmktt-2 | 1 |
| 43 | 1990-7/2002 | 1 |
| 44 | fkbp-12 | 1 |
| 45 | trend=0.012 | 2 |
| 46 | rs274622 | 2 |
| 47 | ttr=2.52 | 1 |
| 48 | μ=2 | 1 |
| 49 | hla-c2 | 1 |
| 50 | catenin-d2 | 1 |
| 51 | nsag2 | 1 |
| 52 | c22h26n4o2 | 1 |
| 53 | amo2 | 1 |
| 54 | cyp2c9*2/*3 | 1 |
| 55 | bmktt-3 | 1 |
| 56 | noninferiority=0.03 | 1 |
| 57 | pcv13/ppsv23/pcv13 | 1 |
| 58 | rs1203633 | 1 |
| 59 | trend=3.833 | 1 |
| 60 | znco3 | 1 |
| 61 | ndufs3 | 1 |
| 62 | 25.0-27.4 | 1 |
| 63 | death=1.04 | 1 |
| 64 | effect=0.004 | 1 |
| 65 | gog114 | 1 |
| 66 | rs3135005 | 1 |
| 67 | rs588765 | 3 |
| 68 | ≤74/≥75 | 1 |
| 69 | d26 | 1 |
| 70 | krasc.146 | 1 |
| 71 | tegobuvir/gs-9256 | 2 |
| 72 | 1993/1996 | 1 |
| 73 | cu-7 | 1 |
| 74 | 0-2.07 | 1 |
| 75 | z907 | 2 |
| 76 | 3,177 | 1 |
| 77 | progression=1.18 | 1 |
| 78 | fne48 | 2 |
| 79 | 13,678 | 1 |
| 80 | hpv-59 | 3 |
| 81 | 26,259 | 1 |
| 82 | pcb169 | 1 |
| 83 | rs10752979 | 1 |
| 84 | lrh-a | 1 |
| 85 | permp-a | 2 |
| 86 | hna-1a | 1 |
| 87 | h1a | 6 |
| 88 | mat1a | 1 |
| 89 | hepg2/c3a | 1 |
| 90 | akt-foxo3a | 1 |
| 91 | hna-4a | 1 |
| 92 | 517a | 2 |
| 93 | longituba | 2 |
| 94 | khuzestanica | 2 |
| 95 | resistant-plasmodia | 1 |
| 96 | fibromyaligia | 1 |
| 97 | d'italia | 1 |
| 98 | anti-hyperglycemia | 1 |
| 99 | hyperklemia | 1 |
| 100 | eukoenenia | 1 |
| 101 | sarcopenia/dynapenia | 1 |
| 102 | antihyperalgesia | 1 |
| 103 | 'pre-dementia | 1 |
| 104 | incana | 2 |
| 105 | coreana | 1 |
| 106 | ayana | 1 |
| 107 | flammna | 1 |
| 108 | 14:0-coa | 1 |
| 109 | haemoprotozoa | 1 |
| 110 | eriocarpa | 1 |
| 111 | tapse/bsa | 1 |
| 112 | apiata | 1 |
| 113 | alwa | 4 |
| 114 | krasnovskaya | 1 |
| 115 | nefrología | 1 |
| 116 | lmktt-1b | 1 |
| 117 | cyp2a61b | 2 |
| 118 | hist1h3b | 1 |
| 119 | hna-4b | 1 |
| 120 | sdhb | 2 |
| 121 | valatanib | 1 |
| 122 | acri/arb | 2 |
| 123 | mtsb | 1 |
| 124 | b-pa-z-c | 1 |
| 125 | b-z-c | 1 |
| 126 | hna-1c | 1 |
| 127 | lmktt-1c | 1 |
| 128 | 517c | 2 |
| 129 | mf.bac | 1 |
| 130 | be/eac | 1 |
| 131 | cardialgic | 1 |
| 132 | demo-socio-economic | 1 |
| 133 | ex-olympic | 1 |
| 134 | amylinomimetic | 1 |
| 135 | benzyl-itc | 2 |
| 136 | 30min/d | 2 |
| 137 | 15min/d | 1 |
| 138 | dfr2d | 1 |
| 139 | mpr/3d | 1 |
| 140 | 165d | 1 |
| 141 | hui2/sf-6d | 1 |
| 142 | hui3/sf-6d | 1 |
| 143 | 810-bed | 1 |
| 144 | unspeeded | 1 |
| 145 | deed | 2 |
| 146 | icu-managed | 1 |
| 147 | day-matched | 2 |
| 148 | e-mail-linked | 1 |
| 149 | anesthesiologist-led | 1 |
| 150 | woman-controlled | 1 |
| 151 | ill-disciplined | 1 |
| 152 | ovoid-shaped | 1 |
| 153 | environment-centred | 1 |
| 154 | aminopyrimidine-based | 1 |
| 155 | stearothermophilus-based | 1 |
| 156 | children-revised | 11 |
| 157 | opg-associated | 1 |
| 158 | energy-mediated | 1 |
| 159 | cholangitis-related | 1 |
| 160 | alkyne-terminated | 1 |
| 161 | ehr-integrated | 1 |
| 162 | fc-mutated | 1 |
| 163 | isopropylidene-protected | 1 |
| 164 | impairment-oriented | 1 |
| 165 | agency-oriented | 1 |
| 166 | mfgm-supplemented | 1 |
| 167 | endovascular-assisted | 1 |
| 168 | 2-benzyloxy-substituted | 1 |
| 169 | ovine-derived | 1 |
| 170 | evolutionary-conserved | 1 |
| 171 | dehumanized | 1 |
| 172 | syncercid | 1 |
| 173 | tetanus-toxoid | 6 |
| 174 | thisdouble-blind | 1 |
| 175 | rtms-first-sham-second | 1 |
| 176 | early-period | 1 |
| 177 | orientation/mood | 1 |
| 178 | a-apd | 1 |
| 179 | schwann/2e | 1 |
| 180 | ospr4e | 1 |
| 181 | spf24nae | 4 |
| 182 | spironolactone-ace | 1 |
| 183 | aircraft/aerospace | 1 |
| 184 | extra-ventricular-device | 1 |
| 185 | intance | 1 |
| 186 | instance | 587 |
| 187 | meth-dependence | 1 |
| 188 | memory/independence | 1 |
| 189 | n-isobutylamide | 1 |
| 190 | n-hydroxysulfenamide | 1 |
| 191 | glutethimide | 1 |
| 192 | intact-side | 1 |
| 193 | n-glucoside | 1 |
| 194 | arteriosonde | 1 |
| 195 | out-docking-mode | 1 |
| 196 | haemorrahage | 1 |
| 197 | β-1,3-linkage | 1 |
| 198 | nonuptake | 1 |
| 199 | kliniske | 19 |
| 200 | klinske | 1 |
| 201 | entero/sigmoidocele | 1 |
| 202 | latreille | 8 |
| 203 | cotrimozaxole | 1 |
| 204 | example | 4,235 |
| 205 | years/lifetime | 1 |
| 206 | ectoenzyme | 1 |
| 207 | benzene-acetylene | 2 |
| 208 | α-copaene/δ-cadinene | 1 |
| 209 | cf₃br.benzene | 1 |
| 210 | allylbenzene | 1 |
| 211 | azadiamidine | 1 |
| 212 | demethylsertraline | 1 |
| 213 | platinum-anthracycline | 1 |
| 214 | venlafaxine-mirtazapine | 2 |
| 215 | carbamazepine/oxcarbazepine | 1 |
| 216 | pseudophedrine | 1 |
| 217 | 2-ethoxymethyl-6-ethyl-2,3,4,5-tetrahydro-1,2,4-triazine-3,5-dione | 1 |
| 218 | 4-estrendione | 1 |
| 219 | new-quinolone | 1 |
| 220 | syringing.none | 1 |
| 221 | analysis.none | 1 |
| 222 | comparisons.none | 1 |
| 223 | participants.none | 1 |
| 224 | aci-reductone | 1 |
| 225 | luts-bpe | 1 |
| 226 | optiscope | 1 |
| 227 | pathotype | 10 |
| 228 | loss-from-care | 3 |
| 229 | researchthere | 2 |
| 230 | eight-core | 1 |
| 231 | δ6-elongase | 2 |
| 232 | encoding-phase | 1 |
| 233 | α-methyl-coa-racemase | 1 |
| 234 | endo-inulinase | 2 |
| 235 | nano-pcpdtbse | 2 |
| 236 | pr-relapse | 1 |
| 237 | child-abuse | 1 |
| 238 | nonabuse | 4 |
| 239 | charge-diffuse | 1 |
| 240 | octylcyanocrylate | 1 |
| 241 | ex-intimate | 1 |
| 242 | sulfadoxine/pyrimethamine-artesunate | 1 |
| 243 | mefloquine/artesunate | 1 |
| 244 | tricyanofluoroborate | 2 |
| 245 | 11-keto-metabolite | 1 |
| 246 | 11-site | 1 |
| 247 | orally-active | 7 |
| 248 | cm.objective | 1 |
| 249 | self-adaptive | 1 |
| 250 | pinkeye | 1 |
| 251 | ch3ch2f | 1 |
| 252 | as-hf | 1 |
| 253 | actual-self | 1 |
| 254 | 5-dsf | 2 |
| 255 | 6-dsf | 2 |
| 256 | rs1799971*g | 1 |
| 257 | tm-e180g | 1 |
| 258 | lactation/kg | 2 |
| 259 | intradural-enhancing | 1 |
| 260 | out-building | 1 |
| 261 | undergirding | 1 |
| 262 | studing | 1 |
| 263 | ct-imaging | 2 |
| 264 | cancer-staging | 1 |
| 265 | hair-blacking | 1 |
| 266 | re-priming | 1 |
| 267 | host-priming | 1 |
| 268 | detection/screening | 1 |
| 269 | diode-pumping | 1 |
| 270 | endocytosis-requiring | 1 |
| 271 | emancipating | 1 |
| 272 | thermo-targeting | 1 |
| 273 | mutual-supplementing | 1 |
| 274 | biotesting | 1 |
| 275 | lying/sitting | 1 |
| 276 | high-utilizing | 1 |
| 277 | s-h | 5 |
| 278 | ≤12h | 1 |
| 279 | ph/pah | 1 |
| 280 | albumin-rich | 1 |
| 281 | oxo-rich | 1 |
| 282 | pbsch | 1 |
| 283 | enantiomorph | 1 |
| 284 | strain/strength | 4 |
| 285 | yhl-i | 3 |
| 286 | transport-i | 2 |
| 287 | pandolfi | 2 |
| 288 | mdi/mdl-aii | 1 |
| 289 | wittichii | 1 |
| 290 | children-iii | 3 |
| 291 | vuralii | 1 |
| 292 | wulii | 1 |
| 293 | fact-btoi | 1 |
| 294 | fischieri | 1 |
| 295 | usssi | 1 |
| 296 | community-associated-uti | 1 |
| 297 | lv-edvi | 1 |
| 298 | pten/pi-3k | 2 |
| 299 | 8-to-10-week | 1 |
| 300 | 82-week | 1 |
| 301 | yoolmok | 1 |
| 302 | quality/risk | 1 |
| 303 | staphlococcal | 1 |
| 304 | itsclinical | 1 |
| 305 | spectrophotometrical | 2 |
| 306 | anti-catarrhal | 1 |
| 307 | strategic/commercial | 1 |
| 308 | trichomonal+bacterial | 1 |
| 309 | accessorial | 1 |
| 310 | immune-abnormal | 1 |
| 311 | e/elateral | 1 |
| 312 | consent/refusal | 1 |
| 313 | resistance/survival | 1 |
| 314 | terbogrel | 2 |
| 315 | fluoxetine.overall | 1 |
| 316 | ruffell | 1 |
| 317 | thorell | 2 |
| 318 | sick/ill | 1 |
| 319 | full/postcard/full | 1 |
| 320 | ng.hr/ml | 5 |
| 321 | α-eudesmol | 1 |
| 322 | 1-acenaphthenol | 1 |
| 323 | functioning/qol | 1 |
| 324 | prevention/control | 1 |
| 325 | 3,4,5,6-inositol | 1 |
| 326 | sulfafurazol | 1 |
| 327 | 2,5-dimethylphenyl | 1 |
| 328 | 3-o-glycosyl | 1 |
| 329 | α-l-rhamnopyrannosyl | 1 |
| 330 | spb-octyl | 1 |
| 331 | parallel-beam | 2 |
| 332 | urocytogram | 1 |
| 333 | bupropion-escitalopram | 1 |
| 334 | piperacillin/sulbactam | 2 |
| 335 | mezlocillin/sulbactam | 2 |
| 336 | lns-10gm | 2 |
| 337 | lns-20gnom | 2 |
| 338 | avellaneum | 1 |
| 339 | sweetgum | 1 |
| 340 | lps-cadmium | 2 |
| 341 | hybernum | 1 |
| 342 | quercetorum | 1 |
| 343 | granulosum | 2 |
| 344 | open-plan | 1 |
| 345 | rs-scn | 2 |
| 346 | antiprogestogen | 3 |
| 347 | copmi-children | 3 |
| 348 | incident-driven | 1 |
| 349 | ebv-driven | 1 |
| 350 | opz/oh-opz/opz-sfn | 1 |
| 351 | yabgn | 1 |
| 352 | fomycin | 1 |
| 353 | metronidazole+clarithromycin | 1 |
| 354 | 10-20min | 1 |
| 355 | 5-120min | 1 |
| 356 | 37.3min | 1 |
| 357 | 16min | 1 |
| 358 | dalcochinin | 1 |
| 359 | pemetrexed-carboplatin-enzastaurin | 2 |
| 360 | aspongopusin | 1 |
| 361 | paclitaxel+carboplatin | 1 |
| 362 | rosucastatin | 1 |
| 363 | tigecycline-colistin | 1 |
| 364 | titrivin | 1 |
| 365 | eco-region | 1 |
| 366 | double-lesion | 1 |
| 367 | kinesiophobia-version | 1 |
| 368 | practice/conclusion | 1 |
| 369 | decoding/classification | 1 |
| 370 | enumeration/identification | 1 |
| 371 | non-elucidation | 1 |
| 372 | refolding/disaggregation | 1 |
| 373 | mri-investigation | 1 |
| 374 | iso-ventilation | 1 |
| 375 | pre-coagulation | 2 |
| 376 | photorejuvenation | 4 |
| 377 | re-impregnation | 2 |
| 378 | cleaning/decontamination | 1 |
| 379 | classification/discrimination | 1 |
| 380 | extraction-fractionation | 1 |
| 381 | restration | 1 |
| 382 | non-registration | 3 |
| 383 | admninistration | 1 |
| 384 | illustration | 154 |
| 385 | distilisation | 2 |
| 386 | co-colonisation | 1 |
| 387 | sanitisation | 1 |
| 388 | re-vegetation | 1 |
| 389 | revision-augmentation | 4 |
| 390 | h2-activation | 1 |
| 391 | dune-fixation | 1 |
| 392 | non-normalization | 1 |
| 393 | c2-functionalization | 1 |
| 394 | bio-functionalization | 1 |
| 395 | feralization | 1 |
| 396 | nanolization | 2 |
| 397 | ameliorization | 1 |
| 398 | angle-correction | 1 |
| 399 | nanoneuroprotection | 1 |
| 400 | photo-induction | 1 |
| 401 | amplification/deletion | 1 |
| 402 | gtv-definition | 1 |
| 403 | prediction/prevention | 1 |
| 404 | failure/interruption | 1 |
| 405 | 4-substitution | 1 |
| 406 | year-season | 1 |
| 407 | zb-crn | 1 |
| 408 | co₂tisn | 2 |
| 409 | muc16/tn | 1 |
| 410 | aian-run | 1 |
| 411 | corcovado | 1 |
| 412 | aucinfo | 1 |
| 413 | irvo | 1 |
| 414 | 515-3p | 2 |
| 415 | mir-371b-3p | 1 |
| 416 | rat8p/dbp5p | 1 |
| 417 | pre-bp | 1 |
| 418 | e/e'-picp | 1 |
| 419 | ocufilm-fingertip | 1 |
| 420 | regrasp | 1 |
| 421 | ambar/fsp | 2 |
| 422 | 100*r | 1 |
| 423 | cerebovascular | 1 |
| 424 | tvr-par | 1 |
| 425 | læger | 1 |
| 426 | effect-modifier | 1 |
| 427 | immunomodifier | 1 |
| 428 | h1-blocker | 2 |
| 429 | oat-biomarker | 1 |
| 430 | oncobiomarker | 1 |
| 431 | primer/vitremer | 1 |
| 432 | entertainer | 1 |
| 433 | e-runner | 1 |
| 434 | cys99ser | 1 |
| 435 | fat/water | 2 |
| 436 | electromanometer | 1 |
| 437 | 8-center | 1 |
| 438 | kouter | 1 |
| 439 | antipsychotic.however | 1 |
| 440 | antiplasticizer | 1 |
| 441 | α4*-nachr | 1 |
| 442 | «major | 1 |
| 443 | arginine-based-inhibitor | 1 |
| 444 | apolipoproteinb-synthesis-inhibitor | 1 |
| 445 | tvr-lead-in-rr | 1 |
| 446 | systolic-sr | 1 |
| 447 | 1xh5n1-as | 5 |
| 448 | 2xh5n1-as | 5 |
| 449 | non-ccrccs | 1 |
| 450 | active-tdcs | 1 |
| 451 | lcnecs | 1 |
| 452 | traumatology/orthopaedics | 1 |
| 453 | trinorsesquiterpenoids | 1 |
| 454 | octa-decabdes | 2 |
| 455 | tetra-hexabdes | 1 |
| 456 | β-1,6-galactooligosaccharides | 1 |
| 457 | indole-2-s-glycosides | 1 |
| 458 | t-stages | 1 |
| 459 | crunches | 1 |
| 460 | dbs-studies | 1 |
| 461 | covarieties | 1 |
| 462 | benignities | 1 |
| 463 | soils/shales | 1 |
| 464 | aching-syndromes | 1 |
| 465 | ectoenzymes | 1 |
| 466 | pro-hormones | 1 |
| 467 | aaa-atpases | 1 |
| 468 | alphaviruses | 1 |
| 469 | vas/wes | 1 |
| 470 | plf+fs | 1 |
| 471 | phospho-motifs | 1 |
| 472 | gowlings | 1 |
| 473 | re-ratings | 1 |
| 474 | antedrugs | 2 |
| 475 | ∑pahs | 1 |
| 476 | sixmonths | 1 |
| 477 | efs-iris | 1 |
| 478 | schistosmiasis | 1 |
| 479 | ldl-apheresis/haemorheopheresis | 1 |
| 480 | kolaensis | 1 |
| 481 | sinkiangensis | 1 |
| 482 | kwangtungensis | 1 |
| 483 | kashmirensis | 1 |
| 484 | dacryostenosis | 1 |
| 485 | fiagnosis | 1 |
| 486 | cryptocaryosis | 1 |
| 487 | eva/stereospsis | 1 |
| 488 | litholysis | 1 |
| 489 | endomyocarditis | 1 |
| 490 | rheumatitis | 1 |
| 491 | sinustitis | 1 |
| 492 | cardioprophylaxis | 1 |
| 493 | 4.5weeks | 1 |
| 494 | 15weeks | 1 |
| 495 | 3-6weeks | 1 |
| 496 | 78weeks | 1 |
| 497 | periodicals | 220 |
| 498 | ordeals | 1 |
| 499 | dbp.trials | 1 |
| 500 | bio-fuels | 2 |
| 501 | slips/trips/falls | 1 |
| 502 | ever-symptoms | 2 |
| 503 | pennsylvanians | 2 |
| 504 | ovo-lacto-vegetarians | 1 |
| 505 | glutelins | 3 |
| 506 | disinfestations | 1 |
| 507 | breast-feeding.comparisons | 1 |
| 508 | timesteps | 1 |
| 509 | analysis.mothers | 1 |
| 510 | non-transitioners | 1 |
| 511 | hitters | 3 |
| 512 | use/repairs | 1 |
| 513 | dose/mass | 3 |
| 514 | needle-less | 2 |
| 515 | hazardless | 2 |
| 516 | suitableness | 1 |
| 517 | ahss | 1 |
| 518 | retweets | 3 |
| 519 | data-sets | 2 |
| 520 | analysis.results | 1 |
| 521 | flexion.coefficients | 1 |
| 522 | i-elements | 1 |
| 523 | p-elements | 1 |
| 524 | mbsr-experts | 1 |
| 525 | rhythmologists | 1 |
| 526 | lysodeikticus | 1 |
| 527 | caldoxylosilyticus | 1 |
| 528 | thermocarboxydus | 1 |
| 529 | avenaceus | 1 |
| 530 | proximus | 2 |
| 531 | active-curious | 1 |
| 532 | age-homogenous | 2 |
| 533 | iniquitous | 1 |
| 534 | lasiopus | 1 |
| 535 | mucilaginosus | 1 |
| 536 | pltxs | 1 |
| 537 | four-days | 2 |
| 538 | 44days | 1 |
| 539 | aitc-lys | 1 |
| 540 | ct+t | 1 |
| 541 | clearing-heat | 1 |
| 542 | individual-threat | 1 |
| 543 | nano-pcpdtbt | 2 |
| 544 | intermodal/intersubject | 1 |
| 545 | easy-to-collect | 1 |
| 546 | earlyonset | 1 |
| 547 | death.it | 1 |
| 548 | evidence-based-albeit | 1 |
| 549 | encapsulant | 4 |
| 550 | puerperant | 2 |
| 551 | anticonvalsant | 1 |
| 552 | acupuncture-relevant | 1 |
| 553 | mirabilis.recent | 2 |
| 554 | aspirin-independent | 1 |
| 555 | amelioration/management | 1 |
| 556 | online-experiment | 1 |
| 557 | eight-treatment | 1 |
| 558 | adjuvant-treatment | 1 |
| 559 | presence/extent | 1 |
| 560 | angora-cont | 2 |
| 561 | low-channel-count | 1 |
| 562 | poot | 1 |
| 563 | yz-pt | 1 |
| 564 | stst-opt | 2 |
| 565 | t2/pre-contrast | 1 |
| 566 | ergonomist | 3 |
| 567 | ar-antagonist | 1 |
| 568 | aromatherapist | 1 |
| 569 | amb-flu | 1 |
| 570 | dtpa-hib-hbv | 1 |
| 571 | tegobuvir/gs-9256/rbv | 2 |
| 572 | non-lbw | 1 |
| 573 | slsmax | 1 |
| 574 | -accuracy | 2 |
| 575 | lipophagy | 1 |
| 576 | otopathy | 1 |
| 577 | spassky | 2 |
| 578 | home/family | 1 |
| 579 | terrestrially | 1 |
| 580 | trichomonal-only | 1 |
| 581 | video-only | 4 |
| 582 | nephroureterctomy | 2 |
| 583 | venovenostomy | 1 |
| 584 | p-diary | 1 |
| 585 | shoulder-axillary | 1 |
| 586 | equerry | 1 |
| 587 | diety | 1 |
| 588 | pain/anxiety | 2 |
| 589 | enteropathogenicity | 1 |
| 590 | overgenerality | 1 |
| 591 | multi-causality | 1 |
| 592 | transformability | 1 |
| 593 | germinability | 1 |
| 594 | noncomparability | 1 |
| 595 | nongeneralizability | 1 |
| 596 | bioavailability/bioaccessibility | 1 |
| 597 | acellularity | 1 |
| 598 | imperiosity | 1 |
| 599 | content/quantity | 2 |
| 600 | prefrailty | 1 |
| 601 | panniculectomy/abdominoplasty | 3 |
| 602 | rhinoplasty/septoplasty | 1 |
| 603 | patient/proxy | 1 |
| 604 | d6-25-oh-d₃ | 1 |
| 605 | self-regulation® | 1 |
| 606 | windows® | 1 |
| 607 | calmette� | 1 |